Medical- and Biotechnology
We know how to secure reimbursement whether it is with selective contracts or through clinical trials according to § 137E SGB V.
Social health insurances and especially the German sick funds increasingly assess the justification for reimbursement based on the evaluation of the added benefit and the budget impact. Are the study results capable to withstand the expectations? Which benefits can the medical company really prove? What effect does the current “standard of care” have on the pricing strategy? These are only some examples of significant levers on which we can work together to achieve sustainable competitive success.
For example, we have accompanied a significant number of products admitted for testing according to § 137e SGB V.